Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Corvus recent rally due to AstraZeneca data, says Roth Capital » 10:41
09/22/21
09/22
10:41
09/22/21
10:41
CRVS

Corvus Pharmaceuticals

$8.09 /

-0.41 (-4.82%)

, AZN

AstraZeneca

$58.64 /

-0.48 (-0.81%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler keeps a Buy rating on Corvus Pharmaceuticals (CRVS) with a $6 price target after the company published an update on its Covid-19 trial for anti-CD73 antibody mupadolimab. This trial is no longer ongoing, yet a Phase I trial with mupadolimab in combination with adenosine A2a receptor antagonist ciforadenant and pembrolizumab against solid tumors continues, Butler tells investors in a research note. The analyst says the recent run Corvus shares is not the result of any data directly related to mupadolimab, however. Rather, the rally is due to lateral competitor AstraZeneca (AZN) presenting data on its anti-CD73 in combination with anti-PD-L1 antibody durvalumab, says Butler. Shares of Corvus Pharmaceuticals are down 4% to $8.21 in morning trading. The analyst notes that mupadolimab currently is in Phase I clinical study for advanced cancers including non-small cell lung, ovarian, bladder, prostate, renal cell carcinoma, colorectal cancer, triplenegative breast, cervical, sarcoma, head and neck and non-Hodgkin's lymphoma.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$8.09 /

-0.41 (-4.82%)

AZN AstraZeneca
$58.64 /

-0.48 (-0.81%)

CRVS Corvus Pharmaceuticals
$8.09 /

-0.41 (-4.82%)

08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
AZN AstraZeneca
$58.64 /

-0.48 (-0.81%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
CRVS Corvus Pharmaceuticals
$8.09 /

-0.41 (-4.82%)

AZN AstraZeneca
$58.64 /

-0.48 (-0.81%)

  • 12
    Feb
AZN AstraZeneca
$58.64 /

-0.48 (-0.81%)

CRVS Corvus Pharmaceuticals
$8.09 /

-0.41 (-4.82%)

AZN AstraZeneca
$58.64 /

-0.48 (-0.81%)

CRVS Corvus Pharmaceuticals
$8.09 /

-0.41 (-4.82%)

AZN AstraZeneca
$58.64 /

-0.48 (-0.81%)

Options
Unusually active option classes on open September 22nd » 09:40
09/22/21
09/22
09:40
09/22/21
09:40
MIC

Macquarie Infrastructure

$40.23 /

+ (+0.00%)

, SOFI

SoFi Technologies

$15.15 /

+ (+0.00%)

, LEN

Lennar

$97.79 /

-0.035 (-0.04%)

, CRVS

Corvus Pharmaceuticals

$8.50 /

+ (+0.00%)

, LCID

Lucid Group

$26.75 /

+ (+0.00%)

, HSBC

HSBC

$24.53 /

+ (+0.00%)

, MOS

Mosaic

$32.42 /

+ (+0.00%)

, BTU

Peabody Energy

$13.99 /

+ (+0.00%)

, BP

BP

$25.22 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Macquarie Infrastructure (MIC), Direxion Daily China Bear 3X Shares (YANG), SoFi Technologies (SOFI), Lennar (LEN), Corvus Pharmaceuticals (CRVS), Lucid Group (LCID), HSBC (HSBC), Mosaic (MOS), Peabody Energy (BTU), and BP (BP).

ShowHide Related Items >><<
SOFI SoFi Technologies
$15.15 /

+ (+0.00%)

MOS Mosaic
$32.42 /

+ (+0.00%)

MIC Macquarie Infrastructure
$40.23 /

+ (+0.00%)

LEN Lennar
$97.79 /

-0.035 (-0.04%)

LCID Lucid Group
$26.75 /

+ (+0.00%)

HSBC HSBC
$24.53 /

+ (+0.00%)

CRVS Corvus Pharmaceuticals
$8.50 /

+ (+0.00%)

BTU Peabody Energy
$13.99 /

+ (+0.00%)

BP BP
$25.22 /

+ (+0.00%)

MIC Macquarie Infrastructure
$40.23 /

+ (+0.00%)

06/16/21 Barclays
Macquarie Infrastructure price target raised to $41 from $34 at Barclays
12/18/20 Truist
Macquarie Infrastructure price target raised to $50 from $35 at Truist
10/15/20 Barclays
Barclays upgrades seven names in Natural Gas and Refining space
10/15/20 Barclays
Macquarie Infrastructure upgraded to Equal Weight from Underweight at Barclays
SOFI SoFi Technologies
$15.15 /

+ (+0.00%)

09/22/21 Jefferies
SoFi Technologies initiated with a Buy at Jefferies
09/14/21 Mizuho
Mizuho starts SoFi with Buy amid 'powerful transition' to 'neo-bank'
09/14/21 Mizuho
SoFi Technologies initiated with a Buy at Mizuho
09/09/21
Fly Intel: Top five analyst initiations
LEN Lennar
$97.79 /

-0.035 (-0.04%)

09/22/21 Wedbush
Lennar price target raised to $120 from $110 at Wedbush
09/22/21 BTIG
Lennar price target raised to $131 from $127 at BTIG
09/22/21 RBC Capital
Lennar price target raised to $102 from $100 at RBC Capital
06/21/21 Argus
Lennar has an edge on many rivals, says Argus
CRVS Corvus Pharmaceuticals
$8.50 /

+ (+0.00%)

08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
LCID Lucid Group
$26.75 /

+ (+0.00%)

09/17/21 Morgan Stanley
520 mile EPA range 'an important milestone' for Lucid, says Morgan Stanley
09/15/21 BofA
BofA calls Lucid the 'Tesla/Ferrari of new EV automakers,' starts at Buy
09/15/21 BofA
Lucid Group initiated with a Buy at BofA
09/13/21 Morgan Stanley
Lucid Group initiated with an Underweight at Morgan Stanley
HSBC HSBC
$24.53 /

+ (+0.00%)

09/17/21 Barclays
HSBC upgraded to Overweight from Underweight at Barclays
09/17/21 RBC Capital
HSBC upgraded to Outperform from Sector Perform at RBC Capital
08/09/21 RBC Capital
HSBC price target lowered to 450 GBp from 480 GBp at RBC Capital
08/05/21 Morgan Stanley
HSBC price target raised to 450 GBp from 430 GBp at Morgan Stanley
MOS Mosaic
$32.42 /

+ (+0.00%)

08/20/21
Fly Intel: Top five analyst upgrades
08/20/21 HSBC
Mosaic upgraded to Buy from Hold at HSBC
08/04/21 RBC Capital
Mosaic price target raised to $50 from $45 at RBC Capital
07/08/21 RBC Capital
Mosaic price target raised to $45 from $43 at RBC Capital
BTU Peabody Energy
$13.99 /

+ (+0.00%)

09/02/21 B. Riley
Peabody Energy price target raised to $15 from $11 at B. Riley
08/02/21 B. Riley
Peabody Energy price target raised to $11 from $7 at B. Riley
07/14/21 B. Riley
Peabody Energy price target raised to $7 from $4 at B. Riley
02/08/21 B. Riley
Peabody Energy price target raised to $3.50 from $1.45 at B. Riley
BP BP
$25.22 /

+ (+0.00%)

09/16/21 Deutsche Bank
BP price target raised to 320 GBp from 313 GBp at Deutsche Bank
08/06/21 Morgan Stanley
BP upgraded to Equal Weight at Morgan Stanley amid record FCF for group
08/06/21 Morgan Stanley
BP upgraded to Equal Weight from Underweight at Morgan Stanley
08/04/21 RBC Capital
BP price target raised to 390 GBp from 350 GBp at RBC Capital
SOFI SoFi Technologies
$15.15 /

+ (+0.00%)

MOS Mosaic
$32.42 /

+ (+0.00%)

LEN Lennar
$97.79 /

-0.035 (-0.04%)

HSBC HSBC
$24.53 /

+ (+0.00%)

CRVS Corvus Pharmaceuticals
$8.50 /

+ (+0.00%)

BTU Peabody Energy
$13.99 /

+ (+0.00%)

BP BP
$25.22 /

+ (+0.00%)

  • 12
    Feb
SOFI SoFi Technologies
$15.15 /

+ (+0.00%)

MOS Mosaic
$32.42 /

+ (+0.00%)

LEN Lennar
$97.79 /

-0.035 (-0.04%)

LCID Lucid Group
$26.75 /

+ (+0.00%)

HSBC HSBC
$24.53 /

+ (+0.00%)

BP BP
$25.22 /

+ (+0.00%)

SOFI SoFi Technologies
$15.15 /

+ (+0.00%)

MOS Mosaic
$32.42 /

+ (+0.00%)

MIC Macquarie Infrastructure
$40.23 /

+ (+0.00%)

LEN Lennar
$97.79 /

-0.035 (-0.04%)

LCID Lucid Group
$26.75 /

+ (+0.00%)

HSBC HSBC
$24.53 /

+ (+0.00%)

CRVS Corvus Pharmaceuticals
$8.50 /

+ (+0.00%)

BTU Peabody Energy
$13.99 /

+ (+0.00%)

BP BP
$25.22 /

+ (+0.00%)

SOFI SoFi Technologies
$15.15 /

+ (+0.00%)

MOS Mosaic
$32.42 /

+ (+0.00%)

LEN Lennar
$97.79 /

-0.035 (-0.04%)

LCID Lucid Group
$26.75 /

+ (+0.00%)

HSBC HSBC
$24.53 /

+ (+0.00%)

CRVS Corvus Pharmaceuticals
$8.50 /

+ (+0.00%)

BTU Peabody Energy
$13.99 /

+ (+0.00%)

BP BP
$25.22 /

+ (+0.00%)

Hot Stocks
Corvus Pharmaceuticals provides update on mupadolimab in viruses and tumors » 06:04
09/22/21
09/22
06:04
09/22/21
06:04
CRVS

Corvus Pharmaceuticals

$8.50 /

+2.35 (+38.21%)

Corvus Pharmaceuticals…

Corvus Pharmaceuticals provided an update on its development programs in oncology and infectious disease for mupadolimab. Corvus is developing mupadolimab as a therapeutic for oncology indications and for infectious disease, starting with COVID-19. Results from its Phase 3 clinical trial of mupadolimab for COVID-19, which cover 40 patients enrolled in the trial prior to its voluntary discontinuation, suggest improvement in the primary and key secondary endpoints in patients treated with single doses of mupadolimab at 2mg/kg and 1mg/kg compared to placebo. No drug related adverse events were reported in the trial. The company believe there is mounting evidence that mupadolimab could become a universal treatment for viral diseases, with the ability to address immune escape from variants. The company plans to evaluate next steps with mupadolimab for COVID-19 as it explores partnership opportunities to continue its development as a therapeutic. Mupadolimab also is currently being studied in a Phase 1b/2 clinical study in patients with HPV+ oropharyngeal cancers and non small cell lung cancers that have failed previous treatment with anti-PD-1 therapy and chemotherapy. Data from the Phase 1b/2 clinical study has been accepted for presentation at the Society for Immunotherapy of Cancer annual meeting in November.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$8.50 /

+2.35 (+38.21%)

CRVS Corvus Pharmaceuticals
$8.50 /

+2.35 (+38.21%)

08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$8.50 /

+2.35 (+38.21%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$8.50 /

+2.35 (+38.21%)

CRVS Corvus Pharmaceuticals
$8.50 /

+2.35 (+38.21%)

Options
Corvus Pharmaceuticals call volume above normal and directionally bullish » 15:25
09/21/21
09/21
15:25
09/21/21
15:25
CRVS

Corvus Pharmaceuticals

$8.74 /

+2.59 (+42.11%)

Bullish option flow…

Bullish option flow detected in Corvus Pharmaceuticals with 31,825 calls trading, 8x expected, and implied vol increasing over 16 points to 222.80%. Oct-21 7.5 calls and Oct-21 10 calls are the most active options, with total volume in those strikes near 23,400 contracts. The Put/Call Ratio is 0.57. Earnings are expected on October 28th.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$8.74 /

+2.59 (+42.11%)

CRVS Corvus Pharmaceuticals
$8.74 /

+2.59 (+42.11%)

08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$8.74 /

+2.59 (+42.11%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$8.74 /

+2.59 (+42.11%)

CRVS Corvus Pharmaceuticals
$8.74 /

+2.59 (+42.11%)

Hot Stocks
Corvus Pharmaceuticals' CPI-818 approved for Phase 1/1b trial in China » 17:05
08/16/21
08/16
17:05
08/16/21
17:05
CRVS

Corvus Pharmaceuticals

$1.88 /

-0.08 (-4.08%)

Corvus…

Corvus Pharmaceuticals' CPI-818 licensee Angel Pharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted its IND application for the initiation of a Phase 1/1b clinical trial of its small molecule ITK inhibitor CPI-818 for treatment of relapsed/refractory T-cell lymphomas. Angel Pharma licensed the rights to CPI-818 from Corvus Pharmaceuticals for development, manufacturing and commercialization in China. Angel Pharmaceuticals announced plans to initiate the trial before the end of 2021. CPI-818 has been shown to selectively inhibit ITK without effect on related kinases. ITK is a 72 kDa protein kinase that plays an essential role in the activation, differentiation and proliferation of T-cells. Based on these properties, ITK is a promising treatment target for autoimmune diseases and for lymphoproliferative diseases such as T-cell lymphomas. Corvus is studying CPI-818 in a multi-center Phase 1/1b clinical trial in patients with several types of TCL in the U.S. and Asia. Overall, CPI-818 has been shown to be well-tolerated, and has shown anti-tumor activity in peripheral T-cell lymphomas and in cutaneous T-cell lymphomas.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$1.88 /

-0.08 (-4.08%)

CRVS Corvus Pharmaceuticals
$1.88 /

-0.08 (-4.08%)

08/03/21 Cantor Fitzgerald
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald
08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$1.88 /

-0.08 (-4.08%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$1.88 /

-0.08 (-4.08%)

CRVS Corvus Pharmaceuticals
$1.88 /

-0.08 (-4.08%)

Recommendations
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald » 07:35
08/03/21
08/03
07:35
08/03/21
07:35
CRVS

Corvus Pharmaceuticals

$2.15 /

+0.045 (+2.14%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Li Watsek lowered the firm's price target on Corvus Pharmaceuticals to $5 from $10 and keeps an Overweight rating on the shares after taking out the opportunity of mupadolimab in COVID-19 following the trial discontinuation and adding the opportunity in HPV+ head and neck cancer.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

08/03/21 Mizuho
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho
07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

Recommendations
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho » 06:37
08/03/21
08/03
06:37
08/03/21
06:37
CRVS

Corvus Pharmaceuticals

$2.15 /

+0.045 (+2.14%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein lowered the firm's price target on Corvus Pharmaceuticals to $3.50 from $4 and keeps a Neutral rating on the shares. The Q2 earnings was as expected following the recent announcement to discontinue the mupadolimab program for the treatment of SARSCoV-2 infected patients, Goldstein tells investors in a research note. The analyst's valuation is based on potential of mupadolimab in a variety of virally-driven cancers.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

07/16/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/26/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $9.50 from $12 at H.C. Wainwright
CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

CRVS Corvus Pharmaceuticals
$2.15 /

+0.045 (+2.14%)

Over a quarter ago
Recommendations
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright » 06:11
07/16/21
07/16
06:11
07/16/21
06:11
CRVS

Corvus Pharmaceuticals

$2.33 /

-0.015 (-0.64%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Corvus Pharmaceuticals to $6 from $9.50 and keeps a Buy rating on the shares. The analyst removed Covid-19 and metastatic castrate-resistant prostate cancer revenues for mupadolimab given the discontinuation of the Phase 3 study.

ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/26/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $9.50 from $12 at H.C. Wainwright
02/10/21 Mizuho
Corvus Pharmaceuticals downgraded to Neutral from Buy at Mizuho
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

On The Fly
Fly Intel: After-Hours Movers » 18:18
07/15/21
07/15
18:18
07/15/21
18:18
AEHR

Aehr Test Systems

$2.80 /

-0.035 (-1.24%)

, MRNA

Moderna

$259.60 /

+13.055 (+5.30%)

, PFDR

Pathfinder Acquisition

$9.76 /

+0.01 (+0.10%)

, AOUT

American Outdoor Brands

$35.75 /

+1.96 (+5.80%)

, MRTN

Marten Transport

$16.81 /

+0.06 (+0.36%)

, CRVS

Corvus Pharmaceuticals

$2.33 /

-0.015 (-0.64%)

Check out this evening's…

ShowHide Related Items >><<
PFDR Pathfinder Acquisition
$9.76 /

+0.01 (+0.10%)

MRNA Moderna
$259.60 /

+13.055 (+5.30%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

AOUT American Outdoor Brands
$35.75 /

+1.96 (+5.80%)

AEHR Aehr Test Systems
$2.80 /

-0.035 (-1.24%)

AEHR Aehr Test Systems
$2.80 /

-0.035 (-1.24%)

MRNA Moderna
$259.60 /

+13.055 (+5.30%)

07/15/21 Jefferies
Moderna price target raised to $250 from $170 at Jefferies
07/07/21 Piper Sandler
Moderna could 'revolutionize' flu vaccine market, says Piper Sandler
06/29/21 Wells Fargo
Moderna vaccine demonstrates activity against key variants, says Wells Fargo
06/29/21 Goldman Sachs
Goldman continues to anticipate clinical need for booster vaccines
PFDR Pathfinder Acquisition
$9.76 /

+0.01 (+0.10%)

AOUT American Outdoor Brands
$35.75 /

+1.96 (+5.80%)

07/02/21 B. Riley
American Outdoor, Vista Outdoor setups remain attractive, says B. Riley
06/28/21 Lake Street
American Outdoor Brands price target raised to $37 from $29 at Lake Street
06/28/21 B. Riley
American Outdoor Brands price target raised to $44 from $38 at B. Riley
03/24/21 B. Riley
American Outdoor Brands price target raised to $38 from $34 at B. Riley
MRTN Marten Transport
$16.81 /

+0.06 (+0.36%)

03/26/21 Vertical Research
Marten Transport initiated with a Buy at Vertical Research
08/07/20 Stephens
FedEx named a Best Idea at Stephens
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/26/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $9.50 from $12 at H.C. Wainwright
02/10/21 Mizuho
Corvus Pharmaceuticals downgraded to Neutral from Buy at Mizuho
MRTN Marten Transport
$16.81 /

+0.06 (+0.36%)

MRNA Moderna
$259.60 /

+13.055 (+5.30%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

AOUT American Outdoor Brands
$35.75 /

+1.96 (+5.80%)

AEHR Aehr Test Systems
$2.80 /

-0.035 (-1.24%)

  • 12
    Feb
PFDR Pathfinder Acquisition
$9.76 /

+0.01 (+0.10%)

MRNA Moderna
$259.60 /

+13.055 (+5.30%)

PFDR Pathfinder Acquisition
$9.76 /

+0.01 (+0.10%)

MRTN Marten Transport
$16.81 /

+0.06 (+0.36%)

MRNA Moderna
$259.60 /

+13.055 (+5.30%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

AOUT American Outdoor Brands
$35.75 /

+1.96 (+5.80%)

MRNA Moderna
$259.60 /

+13.055 (+5.30%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

AOUT American Outdoor Brands
$35.75 /

+1.96 (+5.80%)

Hot Stocks
Corvus Pharmaceuticals trading resumes  16:35
07/15/21
07/15
16:35
07/15/21
16:35
CRVS

Corvus Pharmaceuticals

$2.33 /

-0.015 (-0.64%)

 
ShowHide Related Items >><<
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
05/27/21 Cantor Fitzgerald
Corvus Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
03/26/21 H.C. Wainwright
Corvus Pharmaceuticals price target lowered to $9.50 from $12 at H.C. Wainwright
02/10/21 Mizuho
Corvus Pharmaceuticals downgraded to Neutral from Buy at Mizuho
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

  • 12
    Feb
CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

CRVS Corvus Pharmaceuticals
$2.33 /

-0.015 (-0.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.